20190902 https://www.theguardian.com/science/2019/sep/02/the-science-of-senolytics-how-a-new-pill-could-spell-the-end-of-ageing

20190713 http://www.michaeleisen.org/blog/?p=1480

I hope there may be other offerings from other countries. Why can't there be an unregulated market, where you have companies that are FDA approved, and ones that are not. Let the individual decide.

20190306 https://www.nature.com/articles/d41586-019-00773-y

Strict gene editing regulation in china?

20190228 http://www.sciencemag.org/news/2019/02/crispr-offshoot-still-makes-mistakes-editing-dna-raising-concerns-about-its-medical-use

It says that current attempts at editing germ cells produce errors at 20 times that of background mutation rates. However, this is only for the cytosine base editor. The CRISPR-Cas9 system and the adenine base editors, didn't increase mutation rates. Not too shabby, considering mutation rates are pretty low. Natural background mutation is miraculously low because it has three levels of machinery to correct for errors.

20180712 https://www.fool.com/investing/2018/07/12/keep-your-eyes-on-healthcares-odd-couple-abbvie-an.aspx

“ AbbVie (NYSE:ABBV) and Calico, a life-sciences company funded by Alphabet (NASDAQ:GOOGL), recently announced a three-year extension of their collaboration to develop therapies for age-related diseases, including cancer and neurodegenerative disorders. The two companies first teamed up in 2014. ”

“ Calico's research discovered that the rodent defies laws of mortality. As animals age, their risk of death increases exponentially. That's not true for the naked mole rat, however. The creatures show little signs of aging, and their life-spans far exceed that of other rodents.
Calico's publications also point to significant research into the aging of C. elegans, more commonly known as the roundworm. The company's scientists found that specific genetic mutations in the worm that extend lifespan don't cause feebleness in old age as some researchers thought. ”